Zobrazeno 11 - 20
of 18 800
pro vyhledávání: ''
Autor:
Jessika Contreras, Amar Srivastava, Pamela Samson, Todd DeWees, Ramaswamy Govindan, Maria Q. Baggstrom, Daniel Morgensztern, Michael Roach, Shahed N. Badiyan, Jeffrey Bradley, Saiama Waqar, Clifford Robinson
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 113:742-748
Our purpose was to evaluate the maximum tolerated dose of hypofractionated proton beam radiation therapy with concurrent weekly carboplatin/paclitaxel in patients with stage II-III non-small cell lung cancer.A phase I trial was designed using the tim
Autor:
Nobuyuki Yamamoto, Tetsu Kamitani, Kingo Kanda, Yuichiro Ito, Masahiro Hamada, Masahiko Ozaki, Noriko Takeuchi, Tomoko Yamada, Masaki Kawano, Shinichiroh Maekawa, Terufumi Kato
Publikováno v:
Cancer Science. 113:3110-3119
This post-marketing surveillance (PMS) was initiated in Japan to identify factors affecting the safety and effectiveness of pembrolizumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with programmed cell death ligand-1 (PD
Autor:
Ying, Liu, Changhai, Liu, Yang, Song, Jing, Zhao, Yumin, Gao, Lingyan, Zhao, Ning, Cao, Danni, Xu, Hongwei, Li, Hailing, Li
Publikováno v:
European Journal of Cancer Prevention. 31:530-539
The objective of this study was to evaluate the relationship between short-term fine particulate matter (PM 2.5 )/inhalable particulate matter (PM 10 ) exposure and lung cancer mortality.From 2015 to 2019, data concerning air pollution, meteorology,
Autor:
Hélène Goussault, Sébastien Gendarme, Jean‐Baptiste Assié, Camille Jung, Salomé Epaud, Christelle Algans, Noémie Salaun‐Penquer, Mathilde Rousseau, Andrea Lazatti, Christos Chouaïd
Publikováno v:
Cancer Medicine. 11:5025-5034
Despite therapeutic advances, lung cancer remains the first cause of death from cancer. The main objective of this study was to identify risk factors associated with death within 3-months of the first hospitalization for lung cancer in France.This an
Autor:
Jordi Remon, Benjamin Lacas, Roy Herbst, Martin Reck, Edward B. Garon, Giorgio V. Scagliotti, Rodryg Ramlau, Nasser Hanna, Johan Vansteenkiste, Kiyotaka Yoh, Harry J.M. Groen, John V. Heymach, Sumithra J. Mandrekar, Isamu Okamoto, Joel W. Neal, Rebecca S. Heist, David Planchard, Jean-Pierre Pignon, Benjamin Besse, B. Besse, B. Lacas, J.P. Pignon, J. Remon, T. Berghmans, S. Dahlberg, E. Felip, Thierry Berghmans, Suzanne Dahlberg, Enriqueta Felip, Edward Garon, Alex A. Adjei, Rebecca Heist
Publikováno v:
European Journal of Cancer. 166:112-125
BACKGROUND: Now that immunotherapy plus chemotherapy (CT) is one standard option in first-line treatment of advanced non-small cell lung cancer (NSCLC), there exists a medical need to assess the efficacy of second-line treatments (2LT) with antiangio
Autor:
Yasuyuki Ikezawa, Hidenori Mizugaki, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Megumi Furuta, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Mototsugu Shimokawa, Satoshi Oizumi
Publikováno v:
Cancer Science. 113:2109-2117
It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected for patients with advanced non-small-cell lung cancer (NSCLC) exhibiting high PD-L1 expression (tumor proportion scor
Autor:
Chukwuka Eze, Julian Elias Guggenberger, Nina‐Sophie Schmidt‐Hegemann, Saskia Kenndoff, Julian Taugner, Lukas Käsmann, Stephan Schönecker, Benedikt Flörsch, Minglun Li, Claus Belka, Farkhad Manapov
Publikováno v:
Cancer. 128:2358-2366
The objective of this study was to investigate the feasibility and efficacy of image-guided moderately hypofractionated thoracic radiotherapy (hypo-IGRT) in patients with non-small cell lung cancer (NSCLC) with poor performance status and severely li
Publikováno v:
Nutrition and Cancer. 74:3164-3171
To explore the prognostic value of pretreatment Geriatric Nutrition Risk Index (GNRI) in lung cancer patients.The PubMed, EMBASE and Web of Science electronic databases were searched up to October 5, 2021 for relevant studies. The primary and second
Autor:
Ludovic Fournel, Thomas Charrier, Maxime Huriet, Amedeo Iaffaldano, Audrey Lupo, Diane Damotte, Jennifer Arrondeau, Marco Alifano
Publikováno v:
Lung Cancer. 166:221-227
Prediction of prognosis is a key step of malignant pleural mesothelioma (MPM) management and treatment assignment. Aim of this study was to identify simple prognostic factors, focusing on inflammation-related parameters.Baseline clinical and laborato
Autor:
Vieri Scotti, Beatrice Fantechi, Francesca Mazzoni, I. Stasi, Irene Pecora, Carmelo Tibaldi, Enrico Vasile, Chiara Caparello, Editta Baldini, Marianna Turrini, Lorenzo Antonuzzo, Francesca Federici, Andrea Camerini, Giulia Meoni, Daniele Pozzessere, Diana Giannarelli, Virginia Rossi, L.P. Ciccone
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:1278-1285
Background: In advanced non-small-cell lung cancer, without activating mutations and with PD-L1≥50%, Pembrolizumab monotherapy is the therapeutic standard in Europe. Objective: To evaluate retrospectively the safety and efficacy of this drug and to